Here are the 8-K filings from Quantum Genesis AI Corp (QGAI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow QGAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QGAI filings page.
Quantum Genesis AI Corp. entered into a confirmatory Intellectual Property Assignment Agreement with its Chief Executive Officer, Naveen Kulkarni, on April 9, 2026. The CEO assigned to the company all rights in U.S. Patent Application Publication No. US20250146029A1, covering modified polypeptides for enzymatic synthesis of ibuprofen, together with related current and future intellectual property rights.
The assignment is effective as of November 2, 2023 and is intended to formalize rights the company previously acquired under a February 21, 2023 Asset Purchase Agreement. To reflect this formalization, the company will amend its Form 10-K for the year ended July 31, 2025 and its Form 10-Qs for the quarters ended October 31, 2025 and January 31, 2026 to update disclosures relating to the patent application and any resulting patent.